OverviewSuggest Edit

XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development, and commercialization of therapeutic antibodies based on its True Human™ proprietary technology.

XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess a natural immunity to certain diseases. With the discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight the disease with increased safety, efficacy and tolerability.

XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases.

TypePublic
Founded2005
HQAustin, US
Websitexbiotech.com
Employee Ratings3

Latest Updates

Employees (est.) (Mar 2020)60(+4%)
Share Price (Sept 2020)$20.3 (+2%)
Cybersecurity ratingCMore

Key People/Management at XBiotech

Thorpe McKenzie

Thorpe McKenzie

Director
Jan-Paul Waldin

Jan-Paul Waldin

Director
Donald H. MacAdam

Donald H. MacAdam

Director
Show more

XBiotech Office Locations

XBiotech has an office in Austin
Austin, US (HQ)
5217 Winnebago Ln
Show all (1)

XBiotech Financials and Metrics

XBiotech Revenue

USD

Revenue (Q2, 2020)

15.5m

Gross profit (Q2, 2020)

2.3m

Gross profit margin (Q2, 2020), %

14.8%

Net income (Q2, 2020)

(6.8m)

EBIT (Q2, 2020)

(6.5m)

Market capitalization (22-Sept-2020)

587.8m

Closing stock price (22-Sept-2020)

20.3

Cash (30-Jun-2020)

229.7m
XBiotech's current market capitalization is $587.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

6.2m10.3m7.6m5.3m7.1m

R&D expense

31.3m42.5m26.4m15.7m24.1m

Operating expense total

37.5m52.8m34.1m21.0m31.2m

EBIT

(37.5m)(52.8m)(34.1m)(21.0m)(31.2m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

12.7m15.5m

Cost of goods sold

9.7m13.2m

Gross profit

3.0m2.3m

Gross profit Margin, %

24%15%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

91.1m34.3m31.8m15.8m714.6m

Prepaid Expenses

2.0m1.6m1.2m1.7m

Current Assets

93.0m36.9m33.3m17.0m716.3m

PP&E

5.9m10.1m29.6m27.3m25.2m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

52.2m117.4m105.7m78.2m64.8m46.8m54.6m45.9m39.0m28.4m24.8m20.8m12.0m44.9m40.3m241.5m229.7m

Accounts Receivable

9.7m20.7m

Prepaid Expenses

493.0k3.0m1.9m1.6m1.5m2.0m2.5m1.4m1.3m1.3m917.0k457.0k963.0k678.0k573.0k1.2m802.0k

Current Assets

53.8m120.4m107.6m79.8m66.3m48.8m57.1m47.3m40.3m29.7m25.8m21.3m13.0m45.6m40.9m257.9m258.4m
USDQ1, 2015

Financial Leverage

1.1 x
Show all financial metrics

XBiotech Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

XBiotech Online and Social Media Presence

Embed Graph

XBiotech News and Updates

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed

XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy

After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021 After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical …

XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke

Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therap…

XBiotech Added to NASDAQ Biotechnology Index

AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will become effective prior to market open on Monday, December 23, 2019.

XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use it…

Janssen to Acquire Investigational Bermekimab from XBiotech

HORSHAM, Pa., Dec. 7, 2019 /PRNewswire/ -- Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an...
Show more

XBiotech Blogs

XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients

AUSTIN, Texas , April 03, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration (FDA) investigational program for U.S. blood centers to begin collecting and distributing convalescent

XBiotech Announces Final Results of Tender Offer

AUSTIN, Texas , Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m. , New York City time, on February 12, 2020 . Based on the final count by American Stock Transfer &amp…

Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer

AUSTIN, Texas , Feb. 13, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor.  The corrected press release reads: XBiotech Announces Preliminary Results of Tender Offer XBiotech Inc.

XBiotech Announces Preliminary Results of Tender Offer

AUSTIN, Texas , Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m. , New York City time, on February 12, 2020 . Based on the preliminary count by American Stock

XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares

AUSTIN, Texas , Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly tendered and not properly

XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen

Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline AUSTIN, Texas , Dec. 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today closing of the sale of the Company’s True Human antibody Bermekimab to Janssen Biotech,
Show more

XBiotech Frequently Asked Questions

  • When was XBiotech founded?

    XBiotech was founded in 2005.

  • Who are XBiotech key executives?

    XBiotech's key executives are Thorpe McKenzie, Jan-Paul Waldin and Donald H. MacAdam.

  • How many employees does XBiotech have?

    XBiotech has 60 employees.

  • Who are XBiotech competitors?

    Competitors of XBiotech include Iproteos, Advanced BioDesign and Mironid.

  • Where is XBiotech headquarters?

    XBiotech headquarters is located at 5217 Winnebago Ln, Austin.

  • Where are XBiotech offices?

    XBiotech has an office in Austin.

  • How many offices does XBiotech have?

    XBiotech has 1 office.